Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Inclusion criteria

• Active multiple myeloma in accordance with IMWG criteria，or histopathologically and immunohistochemically confirmed non-Hodgkin's lymphoma in accordance with the 2016 WHO Classification of lymphoid neoplasias.
• Recurred or did not alleviate after the previous treatment.
• Have at least one measurable lesion.
• With a life expectancy of ≥3 months.
• Male or female ≥ 18 years old.
• ECOG performance status of 0-1.
• Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.

Exclusion criteria

• Amyloidosis, plasma cell leukemia.
• Corrected serum calcium>3.4mmol/L(13.5mg/dl).
• Presence of metastasis to central nervous system.
• Treatment of other investigational products.
• Major surgical therapy within 28 days prior to the date of signature of informed consent form, or expected major surgery during the study.
• Known history of hypersensitivity to any components of HRS-3738.
• Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators.